melatonin has been researched along with Intellectual Disability in 32 studies
Intellectual Disability: Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin treatment in persons with ID and chronic insomnia decreases daytime challenging behaviour, probably by improving sleep maintenance or by improving circadian melatonin rhythmicity." | 9.14 | Melatonin decreases daytime challenging behaviour in persons with intellectual disability and chronic insomnia. ( Braam, W; Curfs, LM; Didden, R; Korzilius, H; Maas, AP; Smits, MG, 2010) |
| "Melatonin is used to treat sleep disorders in both children and adults with intellectual disability (ID), although it has no product license for such use." | 8.84 | Melatonin and sleep disorders associated with intellectual disability: a clinical review. ( Clarke, D; Sajith, SG, 2007) |
| "7 years) with neurodevelopmental disorders (n = 29: intellectual disability; n = 9: autism spectrum disorder; n = 7: attention-deficit/hyperactivity disorder) and sleep disturbances, treated with melatonin (mean duration: 326 days) with doses increased according to response." | 7.81 | Melatonin for sleep disturbance in children with neurodevelopmental disorders: prospective observational naturalistic study. ( Ayyash, HF; Cortese, S; Morton, R; Preece, P, 2015) |
| "Our data indicate a disturbed circadian rhythm in melatonin and document the disturbed sleep pattern in Smith-Magenis syndrome." | 7.70 | Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome. ( Glaze, D; Kashork, CD; Lupski, JR; Park, SS; Potocki, L; Reiter, RJ; Shaffer, LG; Tan, DX, 2000) |
| "Melatonin treatment improves some aspects of chronic sleep disturbance in individuals with ID." | 6.73 | Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study. ( Braam, W; Curfs, L; Didden, R; Smits, M, 2008) |
| "Melatonin was initiated at the daily dose of 3 mg, at nocturnal bedtime." | 6.71 | Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. ( Coppola, G; Iervolino, G; La Torre, G; Mastrosimone, M; Pascotto, A; Ruiu, F, 2004) |
| "Smith-Magenis syndrome (SMS) is a mental retardation syndrome with distinctive behavioral characteristics, dysmorphic features and congenital anomalies ascribed to an interstitial deletion of chromosome 17p11." | 6.43 | Inverted rhythm of melatonin secretion in Smith-Magenis syndrome: from symptoms to treatment. ( De Leersnyder, H, 2006) |
| "Treatment with melatonin demonstrated efficacy, suggesting that, at least in a subgroup of patients, the endogenous melatonin level may not be sufficient to adequately set the sleep-wake cycles." | 5.37 | Mutation screening of ASMT, the last enzyme of the melatonin pathway, in a large sample of patients with intellectual disability. ( Botros, HG; Bourgeron, T; Briault, S; Chelly, J; de Brouwer, A; Delorme, R; Dumaine, A; Jamain, S; Kalscheuer, V; Lacombe, D; Laumonnier, F; Launay, JM; Leboyer, M; Moreno, S; Pagan, C; Poirier, K; Raynaud, M; Tzschach, A; van Bon, BW; Van Esch, H; Willemsen, MH, 2011) |
| "Mental retardation is constant; there are major behavioral disturbances and severe sleep disorders." | 5.32 | [Inversion of the circadian melatonin rhythm in Smith-Magenis syndrome]. ( Bresson, JL; Claustrat, B; de Blois, MC; De Leersnyder, H; Munnich, A; Sidi, D, 2003) |
| "Melatonin treatment in persons with ID and chronic insomnia decreases daytime challenging behaviour, probably by improving sleep maintenance or by improving circadian melatonin rhythmicity." | 5.14 | Melatonin decreases daytime challenging behaviour in persons with intellectual disability and chronic insomnia. ( Braam, W; Curfs, LM; Didden, R; Korzilius, H; Maas, AP; Smits, MG, 2010) |
| "Melatonin is used to treat sleep disorders in both children and adults with intellectual disability (ID), although it has no product license for such use." | 4.84 | Melatonin and sleep disorders associated with intellectual disability: a clinical review. ( Clarke, D; Sajith, SG, 2007) |
| " This article focuses on the following specific neurologic diseases: nocturnal frontal lobe epilepsy and abnormal motor behaviors of epileptic origin, evaluating differential diagnosis with parasomnias; achondroplasia, confirming the crucial role of craniofacial deformity in determining sleep-disordered breathing; neuromuscular diseases, mainly Duchenne's muscular dystrophy and myotonic dystrophy; cerebral palsy, evaluating either the features of sleep architecture and the importance of the respiratory problems associated; headaches, confirming the strict relationships with sleep in terms of neurochemical and neurobehavioral substrates; and finally a review on the effectiveness of melatonin for sleep problems in children with neurologic syndromes and mental retardation, blindness, and epilepsy." | 4.81 | Sleep disorders in children with neurologic diseases. ( Bruni, O; Zucconi, M, 2001) |
| "7 years) with neurodevelopmental disorders (n = 29: intellectual disability; n = 9: autism spectrum disorder; n = 7: attention-deficit/hyperactivity disorder) and sleep disturbances, treated with melatonin (mean duration: 326 days) with doses increased according to response." | 3.81 | Melatonin for sleep disturbance in children with neurodevelopmental disorders: prospective observational naturalistic study. ( Ayyash, HF; Cortese, S; Morton, R; Preece, P, 2015) |
| "In this study, we determined melatonin clearance in two female (aged 61 and 6 years) and one male (aged 3 years) patients who had chronic insomnia, late melatonin onset and mild ID, and whose sleep quality worsened a few weeks after initial good response to melatonin treatment, suggesting melatonin tolerance." | 3.76 | Loss of response to melatonin treatment is associated with slow melatonin metabolism. ( Braam, W; Curfs, LM; Didden, R; Keijzer, H; Smits, MG; van Geijlswijk, I, 2010) |
| "Our data indicate a disturbed circadian rhythm in melatonin and document the disturbed sleep pattern in Smith-Magenis syndrome." | 3.70 | Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome. ( Glaze, D; Kashork, CD; Lupski, JR; Park, SS; Potocki, L; Reiter, RJ; Shaffer, LG; Tan, DX, 2000) |
| "Melatonin treatment improves some aspects of chronic sleep disturbance in individuals with ID." | 2.73 | Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study. ( Braam, W; Curfs, L; Didden, R; Smits, M, 2008) |
| "Melatonin was initiated at the daily dose of 3 mg, at nocturnal bedtime." | 2.71 | Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. ( Coppola, G; Iervolino, G; La Torre, G; Mastrosimone, M; Pascotto, A; Ruiu, F, 2004) |
| "Smith-Magenis syndrome (SMS) is a mental retardation syndrome with distinctive behavioral characteristics, dysmorphic features and congenital anomalies ascribed to an interstitial deletion of chromosome 17p11." | 2.43 | Inverted rhythm of melatonin secretion in Smith-Magenis syndrome: from symptoms to treatment. ( De Leersnyder, H, 2006) |
| "Treatment with melatonin demonstrated efficacy, suggesting that, at least in a subgroup of patients, the endogenous melatonin level may not be sufficient to adequately set the sleep-wake cycles." | 1.37 | Mutation screening of ASMT, the last enzyme of the melatonin pathway, in a large sample of patients with intellectual disability. ( Botros, HG; Bourgeron, T; Briault, S; Chelly, J; de Brouwer, A; Delorme, R; Dumaine, A; Jamain, S; Kalscheuer, V; Lacombe, D; Laumonnier, F; Launay, JM; Leboyer, M; Moreno, S; Pagan, C; Poirier, K; Raynaud, M; Tzschach, A; van Bon, BW; Van Esch, H; Willemsen, MH, 2011) |
| "Mental retardation is constant; there are major behavioral disturbances and severe sleep disorders." | 1.32 | [Inversion of the circadian melatonin rhythm in Smith-Magenis syndrome]. ( Bresson, JL; Claustrat, B; de Blois, MC; De Leersnyder, H; Munnich, A; Sidi, D, 2003) |
| "Melatonin treatment increased nighttime sleep from 5." | 1.31 | Melatonin improves sleep-wake patterns in psychomotor retarded children. ( Etzioni, A; Lavie, P; Peled, N; Pillar, G; Ravid, S; Shahar, E, 2000) |
| "Melatonin is a well-tolerated, safe, relatively inexpensive, and effective drug, with minimal side effects, for the treatment of severe circadian rhythm sleep disorder in handicapped children." | 1.31 | Melatonin for the treatment of handicapped children with severe sleep disorders. ( Jan, MM, 2000) |
| "A 9-year-old, blind boy with severe mental retardation with a chronic sleep/wake disturbance had a circadian rhythm of 24." | 1.28 | Correction of non-24-hour sleep/wake cycle by melatonin in a blind retarded boy. ( Blennow, G; Palm, L; Wetterberg, L, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 4 (12.50) | 18.2507 |
| 2000's | 18 (56.25) | 29.6817 |
| 2010's | 9 (28.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Won, J | 1 |
| Jin, Y | 1 |
| Choi, J | 1 |
| Park, S | 1 |
| Lee, TH | 1 |
| Lee, SR | 1 |
| Chang, KT | 1 |
| Hong, Y | 1 |
| Benabou, M | 1 |
| Rolland, T | 1 |
| Leblond, CS | 1 |
| Millot, GA | 1 |
| Huguet, G | 1 |
| Delorme, R | 2 |
| Leboyer, M | 2 |
| Pagan, C | 2 |
| Callebert, J | 1 |
| Maronde, E | 1 |
| Bourgeron, T | 2 |
| Albrecht, M | 1 |
| Zitta, K | 1 |
| Groenendaal, F | 1 |
| van Bel, F | 1 |
| Peeters-Scholte, C | 1 |
| Ayyash, HF | 1 |
| Preece, P | 1 |
| Morton, R | 1 |
| Cortese, S | 1 |
| McAdams, RM | 1 |
| Juul, SE | 1 |
| Hamers, PC | 1 |
| Evenhuis, HM | 1 |
| Hermans, H | 1 |
| Braam, W | 4 |
| Smits, MG | 3 |
| Didden, R | 4 |
| Korzilius, H | 2 |
| Van Geijlswijk, IM | 1 |
| Curfs, LM | 3 |
| Boudreau, EA | 1 |
| Johnson, KP | 1 |
| Jackman, AR | 1 |
| Blancato, J | 1 |
| Huizing, M | 1 |
| Bendavid, C | 1 |
| Jones, M | 1 |
| Chandrasekharappa, SC | 1 |
| Lewy, AJ | 1 |
| Smith, AC | 1 |
| Magenis, RE | 1 |
| Maas, AP | 1 |
| van Geijlswijk, I | 1 |
| Keijzer, H | 1 |
| Botros, HG | 1 |
| Poirier, K | 1 |
| Dumaine, A | 1 |
| Jamain, S | 1 |
| Moreno, S | 1 |
| de Brouwer, A | 1 |
| Van Esch, H | 1 |
| Launay, JM | 1 |
| Tzschach, A | 1 |
| Kalscheuer, V | 1 |
| Lacombe, D | 1 |
| Briault, S | 1 |
| Laumonnier, F | 1 |
| Raynaud, M | 1 |
| van Bon, BW | 1 |
| Willemsen, MH | 1 |
| Chelly, J | 1 |
| Niederhofer, H | 1 |
| Staffen, W | 1 |
| Mair, A | 1 |
| Pittschieler, K | 1 |
| Cornélissen, G | 1 |
| Halberg, F | 1 |
| Tarquini, R | 1 |
| Perfetto, F | 1 |
| Salti, R | 1 |
| Laffi, G | 1 |
| Otsuka, K | 1 |
| De Leersnyder, H | 2 |
| de Blois, MC | 1 |
| Bresson, JL | 1 |
| Sidi, D | 1 |
| Claustrat, B | 1 |
| Munnich, A | 1 |
| Coppola, G | 1 |
| Iervolino, G | 1 |
| Mastrosimone, M | 1 |
| La Torre, G | 1 |
| Ruiu, F | 1 |
| Pascotto, A | 1 |
| Wheeler, B | 1 |
| Taylor, B | 1 |
| Simonsen, K | 1 |
| Reith, DM | 1 |
| Sajith, SG | 1 |
| Clarke, D | 1 |
| Bersani, G | 1 |
| Russo, D | 1 |
| Limpido, L | 1 |
| Marconi, D | 1 |
| Laakso, ML | 1 |
| Lindblom, N | 1 |
| Leinonen, L | 1 |
| Kaski, M | 1 |
| Smits, M | 1 |
| Curfs, L | 1 |
| Dodd, A | 1 |
| Hare, DJ | 1 |
| Arshad, P | 1 |
| Ito, J | 1 |
| Saijo, H | 1 |
| Tanaka, H | 1 |
| Tasaki, T | 1 |
| Chou, K | 1 |
| Camfield, P | 1 |
| Gordon, K | 1 |
| Dooley, J | 1 |
| Camfield, C | 1 |
| Lancioni, GE | 1 |
| O'Reilly, MF | 1 |
| Basili, G | 1 |
| Potocki, L | 1 |
| Glaze, D | 1 |
| Tan, DX | 1 |
| Park, SS | 1 |
| Kashork, CD | 1 |
| Shaffer, LG | 1 |
| Reiter, RJ | 1 |
| Lupski, JR | 1 |
| Pillar, G | 1 |
| Shahar, E | 1 |
| Peled, N | 1 |
| Ravid, S | 1 |
| Lavie, P | 1 |
| Etzioni, A | 1 |
| Jan, MM | 1 |
| Akaboshi, S | 1 |
| Inoue, Y | 1 |
| Kubota, N | 1 |
| Takeshita, K | 1 |
| Zucconi, M | 1 |
| Bruni, O | 1 |
| Palm, L | 1 |
| Blennow, G | 1 |
| Wetterberg, L | 1 |
| Woolley, DW | 1 |
| Van der Hoeven, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Autophagy, Mitophagy, Inflammation and Plasmatic Concentration of Melatonin in Newborn With Metabolic Acidosis at Birth[NCT03897101] | 150 participants (Anticipated) | Observational [Patient Registry] | 2019-03-01 | Recruiting | |||
| Use of Melatonin for Neuroprotection in Term Infants With Hypoxic-ischaemic Encephalopathy[NCT03806816] | 100 participants (Anticipated) | Interventional | 2018-12-13 | Recruiting | |||
| Controlled-Release Melatonin (Melatonin CR)for the Treatment of Impaired Sleep Maintenance (ISM) in 4-8 Year Old Children With Autism Spectrum Disorders (ASD).[NCT01033565] | Phase 4 | 1 participants (Actual) | Interventional | 2010-03-04 | Terminated (stopped due to Unsuccessful in recruiting appropriate subjects.) | ||
| Melatonin Levels in Sleep-disordered Smith-Magenis Syndrome: a Pilot Study[NCT00691574] | 5 participants (Actual) | Interventional | 1998-09-30 | Terminated (stopped due to Unique provision in the American Recovery and Reinvestment Act prevented approval of second year no-cost-extension in which completion of analyses were planned.) | |||
| Characterization of Endogenous Melatonin Profiles in Children With Autism Spectrum Disorder.[NCT00691080] | 58 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assigns numerical score indicating level of improvement compared to baseline. Scale is rated from 1-7: 1= very much improved; 2= much improved; 3= minimally improved; 4= no change; 5= minimally worse; 6= much worse; 7= very much worse. (NCT01033565)
Timeframe: 2 weeks
| Intervention | units on a scale (Number) |
|---|---|
| Natrol | 2 |
8 reviews available for melatonin and Intellectual Disability
| Article | Year |
|---|---|
Melatonin as a Novel Interventional Candidate for Fragile X Syndrome with Autism Spectrum Disorder in Humans.
Topics: Anxiety; Autism Spectrum Disorder; Circadian Clocks; Circadian Rhythm; Fragile X Mental Retardation | 2017 |
Neuroprotective strategies following perinatal hypoxia-ischemia: Taking aim at NOS.
Topics: Allopurinol; Asphyxia Neonatorum; Biotin; Cerebral Palsy; Clinical Trials as Topic; Epilepsy; Erythr | 2019 |
Neonatal Encephalopathy: Update on Therapeutic Hypothermia and Other Novel Therapeutics.
Topics: Anesthetics, Inhalation; Biotin; Central Nervous System Depressants; Cerebral Palsy; Constriction; E | 2016 |
Neonatal Encephalopathy: Update on Therapeutic Hypothermia and Other Novel Therapeutics.
Topics: Anesthetics, Inhalation; Biotin; Central Nervous System Depressants; Cerebral Palsy; Constriction; E | 2016 |
Neonatal Encephalopathy: Update on Therapeutic Hypothermia and Other Novel Therapeutics.
Topics: Anesthetics, Inhalation; Biotin; Central Nervous System Depressants; Cerebral Palsy; Constriction; E | 2016 |
Neonatal Encephalopathy: Update on Therapeutic Hypothermia and Other Novel Therapeutics.
Topics: Anesthetics, Inhalation; Biotin; Central Nervous System Depressants; Cerebral Palsy; Constriction; E | 2016 |
Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta-analysis.
Topics: Angelman Syndrome; Central Nervous System Depressants; Child; Child Development Disorders, Pervasive | 2009 |
Inverted rhythm of melatonin secretion in Smith-Magenis syndrome: from symptoms to treatment.
Topics: Abnormalities, Multiple; Circadian Rhythm; Humans; Intellectual Disability; Melatonin; Sleep Wake Di | 2006 |
Melatonin and sleep disorders associated with intellectual disability: a clinical review.
Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Dr | 2007 |
Review of strategies for treating sleep problems in persons with severe or profound mental retardation or multiple handicaps.
Topics: Adolescent; Adult; Behavior Therapy; Child; Chronotherapy; Developmental Disabilities; Female; Human | 1999 |
Sleep disorders in children with neurologic diseases.
Topics: Anticonvulsants; Blindness; Child; Child, Preschool; Diagnosis, Differential; Epilepsy; Headache; Hu | 2001 |
7 trials available for melatonin and Intellectual Disability
| Article | Year |
|---|---|
A multicenter randomized controlled trial for bright light therapy in adults with intellectual disabilities and depression: Study protocol and obstacle management.
Topics: Actigraphy; Adult; Circadian Rhythm; Depression; Depressive Disorder, Major; Hair; Humans; Hydrocort | 2017 |
Melatonin decreases daytime challenging behaviour in persons with intellectual disability and chronic insomnia.
Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Circadian Rhythm; Female; Humans; Intel | 2010 |
Brief report: melatonin facilitates sleep in individuals with mental retardation and insomnia.
Topics: Administration, Oral; Adolescent; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admini | 2003 |
Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Cros | 2004 |
Melatonin treatment in Smith Magenis syndrome.
Topics: Antioxidants; Chronobiology Disorders; Double-Blind Method; Humans; Intellectual Disability; Melaton | 2005 |
Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study.
Topics: Adolescent; Adult; Aged; Central Nervous System Depressants; Child; Child, Preschool; Chronic Diseas | 2008 |
Melatonin appears ineffective in children with intellectual deficits and fragmented sleep: six "N of 1" trials.
Topics: Adolescent; Child; Child, Preschool; Double-Blind Method; Female; Humans; Intellectual Disability; M | 1996 |
17 other studies available for melatonin and Intellectual Disability
| Article | Year |
|---|---|
Heritability of the melatonin synthesis variability in autism spectrum disorders.
Topics: Adolescent; Adult; Arylalkylamine N-Acetyltransferase; Autism Spectrum Disorder; Child; Endophenotyp | 2017 |
Melatonin for sleep disturbance in children with neurodevelopmental disorders: prospective observational naturalistic study.
Topics: Analysis of Variance; Central Nervous System Depressants; Child; Child, Preschool; Dose-Response Rel | 2015 |
Review of disrupted sleep patterns in Smith-Magenis syndrome and normal melatonin secretion in a patient with an atypical interstitial 17p11.2 deletion.
Topics: Abnormalities, Multiple; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Humans; Intellect | 2009 |
Loss of response to melatonin treatment is associated with slow melatonin metabolism.
Topics: Child; Child, Preschool; Drug Tolerance; Female; Humans; Intellectual Disability; Male; Melatonin; M | 2010 |
Mutation screening of ASMT, the last enzyme of the melatonin pathway, in a large sample of patients with intellectual disability.
Topics: Acetylserotonin O-Methyltransferase; Case-Control Studies; Genetic Testing; Humans; Intellectual Dis | 2011 |
Point and interval estimations of circadian melatonin ecphasia in Smith-Magenis syndrome.
Topics: Adolescent; Adult; Child; Chromosome Deletion; Chromosomes, Human, Pair 17; Congenital Abnormalities | 2003 |
[Inversion of the circadian melatonin rhythm in Smith-Magenis syndrome].
Topics: Abnormalities, Multiple; Adolescent; Adrenergic beta-Antagonists; Child; Child, Preschool; Chromosom | 2003 |
Mood disorder in a patient with Smith-Magenis syndrome: a case report.
Topics: Adult; Chromosomes, Human, Pair 17; Craniofacial Abnormalities; Female; Gene Deletion; Humans; Intel | 2007 |
Endogenous melatonin predicts efficacy of exogenous melatonin in consolidation of fragmented wrist-activity rhythm of adult patients with developmental brain disorders: a double-blind, placebo-controlled, crossover study.
Topics: Adult; Circadian Rhythm; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; | 2007 |
The use of melatonin to treat sleep disorder in adults with intellectual disabilities in community settings - the evaluation of three cases using actigraphy.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hu | 2008 |
[Melatonin treatment for sleep-wake disorder--an experience for a severely mental retarded patient with blindness].
Topics: Administration, Oral; Blindness; Child; Circadian Rhythm; Humans; Intellectual Disability; Male; Mel | 1995 |
Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome.
Topics: Abnormalities, Multiple; Adolescent; Adult; Child; Child, Preschool; Chromosomes, Human, Pair 17; Ci | 2000 |
Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome.
Topics: Abnormalities, Multiple; Adolescent; Adult; Child; Child, Preschool; Chromosomes, Human, Pair 17; Ci | 2000 |
Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome.
Topics: Abnormalities, Multiple; Adolescent; Adult; Child; Child, Preschool; Chromosomes, Human, Pair 17; Ci | 2000 |
Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome.
Topics: Abnormalities, Multiple; Adolescent; Adult; Child; Child, Preschool; Chromosomes, Human, Pair 17; Ci | 2000 |
Melatonin improves sleep-wake patterns in psychomotor retarded children.
Topics: Adolescent; Child; Child, Preschool; Circadian Rhythm; Female; Humans; Intellectual Disability; Male | 2000 |
Melatonin for the treatment of handicapped children with severe sleep disorders.
Topics: Child; Child, Preschool; Circadian Rhythm; Disabled Children; Drug Administration Schedule; Female; | 2000 |
Case of a mentally retarded child with non-24 hour sleep-wake syndrome caused by deficiency of melatonin secretion.
Topics: Administration, Oral; Child, Preschool; Humans; Hydrocortisone; Intellectual Disability; Male; Melat | 2000 |
Correction of non-24-hour sleep/wake cycle by melatonin in a blind retarded boy.
Topics: Blindness; Child; Circadian Rhythm; Humans; Hydrocortisone; Intellectual Disability; Male; Melatonin | 1991 |
Serotonin deficiency in infancy as a cause of a mental defect in experimental phenylketonuria.
Topics: 5-Hydroxytryptophan; Animals; Animals, Newborn; Chlorpromazine; Electroshock; Female; Humans; In Vit | 1965 |